An Open-Label, Phase I/II Trial Of ABI-007 (A CREMOPHOR El-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly In Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

An Open-Label, Phase I/II Trial Of ABI-007 (A CREMOPHOR El-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly In Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2012

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Aug 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top